Document Preview Unavailable
Sufficiency of Single‐Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib
You might have access to this document
-
Try and log in through your institution to see if they have access to the full text.
Log in through your library